Teladoc Health Reports Strong Q1 Revenue Growth Amid EPS Miss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Source: seekingalpha
Teladoc Health Inc. saw its stock rise by 6.44% as it crossed above the 5-day SMA, reflecting positive market conditions. The company reported Q1 2026 revenue of $614 million, exceeding analysts' expectations of $611 million, despite a GAAP EPS loss of -$0.36, which missed expectations by $0.02. This revenue growth was driven by the expansion of its insurance market presence, now active in 30 states and Washington D.C., with over 6,000 credentialed providers, indicating strong potential for future revenue growth.
Despite the EPS miss, Teladoc's optimistic future outlook includes projected consolidated revenue for 2026 between $2.48 billion and $2.58 billion, with adjusted EBITDA expected to range from $267 million to $306 million. The management's confidence is particularly bolstered by the performance of BetterHelp's insurance business, which is expected to contribute significantly to revenue. However, ongoing challenges in profitability may influence investor sentiment moving forward.
The implications of Teladoc's performance suggest a resilient business model amid market fluctuations, with a focus on expanding its integrated care services. The company's ability to adapt and grow in the insurance market could position it favorably for future success, despite short-term profitability concerns.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TDOC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TDOC
Wall Street analysts forecast TDOC stock price to rise
15 Analyst Rating
3 Buy
12 Hold
0 Sell
Hold
Current: 7.510
Low
7.50
Averages
8.91
High
12.00
Current: 7.510
Low
7.50
Averages
8.91
High
12.00
About TDOC
Teladoc Health, Inc. provides virtual healthcare services. Its segments include Teladoc Health Integrated Care (Integrated Care) and BetterHelp. Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. Services in this segment are distributed on a B2B basis. BetterHelp segment includes direct-to-consumer mental health platform. The online counseling and therapy services are provided via its network of over 35,000 licensed clinicians leveraging its platform for Web, mobile app, phone, and text-based interactions. Its Teladoc Health family of brands, including Teladoc and BetterHelp, deliver access to advice and resolution for an array of healthcare needs. Its Telecare brand is a tech-enabled provider of specialist and allied health care via virtual delivery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Teladoc Partners with Walmart for Virtual Care Services
- Partnership Expansion: Teladoc's collaboration with Walmart aims to provide virtual urgent care, dermatology, and nutrition services through the Better Care Services platform, targeting uninsured or underinsured demographics, which is expected to broaden its customer base.
- Service Details: The offerings include 24/7 virtual urgent care, dermatology consultations with a 24-hour turnaround, and nutrition coaching, priced at $89 per visit, with prescriptions sent to any pharmacy, including Walmart.
- Market Reaction: Following the announcement of the partnership, Teladoc's shares rose over 7%, surpassing the 200-day moving average, indicating a positive market response to the collaboration.
- Strategic Implications: Bank of America views this partnership as a 'modest positive' for Teladoc, although it does not expect significant financial impacts in the near term; nonetheless, it enhances Teladoc's service integration within retail platforms, boosting brand visibility.
See More
Teladoc Partners with Walmart to Expand Virtual Care Services
- Collaboration Expansion: Teladoc Health announced that its virtual care services are now available through Walmart's Better Care Services platform, aiming to enhance access to healthcare, particularly for uninsured customers.
- Service Offerings: The new partnership allows Walmart customers to access various medical services, including 24/7 care, dermatology, and nutrition services, for $89 per visit, significantly improving the healthcare experience for shoppers.
- Market Strategy: Teladoc's president, Kelly Bliss, emphasized that Walmart is a primary destination for everyday needs for millions of Americans, and integrating healthcare services into the shopping experience enhances brand penetration in the market.
- Historical Collaborations: This partnership is part of Teladoc's ongoing collaboration with Walmart, following its 2025 partnership with Amazon to offer diabetes and hypertension management programs, showcasing its strategic positioning in retail and online platforms.
See More
Teladoc Health's Uncertain Future Raises Concerns
- Subpar Financial Performance: In its first quarter update, Teladoc reported a 2% year-over-year revenue decline to $613.8 million, and while the net loss per share improved from $0.53 to $0.36, the company remains unprofitable, indicating significant challenges in regaining growth momentum.
- Decline of BetterHelp Segment: Once a key growth driver, BetterHelp has seen both revenue and paying users drop by 9% year-over-year, highlighting difficulties in sustaining growth in a competitive market, which negatively impacts overall company performance.
- International Expansion Potential: Despite overall struggles, Teladoc's international revenue increased by 17% year-over-year to $122.3 million, suggesting potential for future revenue growth as the company taps into global markets.
- Uncertain Future of AI Tools: Teladoc's plans to introduce AI products to boost revenue face uncertainty regarding their effectiveness, and combined with ongoing losses and fierce competition, investors remain cautious about the company's ability to achieve profitability in the future.
See More
Teladoc Health Struggles with Financial Performance
- Declining Financial Performance: Teladoc's stock has plummeted over 90% in the past five years, with Q1 revenue dropping 2% year-over-year to $613.8 million; despite an improvement in net loss per share from $0.53 to $0.36, the company remains unprofitable, indicating ongoing financial struggles.
- BetterHelp Segment Decline: Once a key growth driver, BetterHelp has seen both revenue and paying users decline by 9% year-over-year, highlighting challenges in sustaining growth in a competitive market, which adversely affects overall performance.
- International Expansion Potential: Despite poor overall performance, Teladoc's international revenue rose 17% year-over-year to $122.3 million, indicating potential for future revenue growth as the company taps into global markets.
- Uncertain Future of AI Tools: Teladoc plans to introduce a range of AI products to boost revenue; however, given the company's history of consistent losses and intense market competition, the success of this strategy remains highly uncertain.
See More
Teladoc Stock Underperforms, Caution Advised for Investors
- Weak Revenue Growth: Teladoc's sales of $2.51 billion over the past 12 months are nearly unchanged from three years ago, indicating a lack of long-term revenue growth and suggesting lower overall business quality, which may undermine investor confidence.
- Declining User Spending: The average revenue per user (ARPU) has decreased by an average of 9% annually over the past two years, raising concerns about user engagement and signaling a potential erosion of the platform's value, which could impact future revenue growth.
- Soft Future Revenue Projections: Wall Street analysts expect Teladoc's revenue to stagnate over the next 12 months, a forecast that fails to excite the market and suggests that its newer products and services are not poised to accelerate revenue growth, potentially putting pressure on the stock price.
- Poor Market Performance: Currently trading at $6.81 per share with a forward EV/EBITDA of 5.1x, Teladoc's valuation appears fair, but the limited upside compared to potential downside risks suggests investors should consider more attractive investment opportunities.
See More
Teladoc Health Shares Rise for Seven Consecutive Days
- Stock Price Surge: Teladoc Health's shares rose over 4% on Friday, marking a seven-day winning streak, with a 22% increase since April 30, climbing from $5.95 to approximately $7.30, indicating strong market optimism about its future prospects.
- Strong Monthly Performance: Over the past month, Teladoc's stock has gained 38%, although it is up only 2.7% year-to-date, trailing the S&P 500's approximately 7% gains, reflecting a need for improvement in its relative market performance.
- Business Model Transformation: Analysts highlight that Teladoc is transitioning from a cyclical direct-to-consumer telehealth model to a higher-margin, data-driven business-to-business healthcare platform, which could enhance its long-term profitability and market valuation.
- Improved Financial Health: With improving EBITDA margins, positive free cash flow, and a stronger balance sheet, Teladoc is seen as entering a more scalable profitability phase, supporting potential future valuation re-ratings.
See More
Teladoc Partners with Walmart for Virtual Care Services
- Partnership Expansion: Teladoc's collaboration with Walmart aims to provide virtual urgent care, dermatology, and nutrition services through the Better Care Services platform, targeting uninsured or underinsured demographics, which is expected to broaden its customer base.
- Service Details: The offerings include 24/7 virtual urgent care, dermatology consultations with a 24-hour turnaround, and nutrition coaching, priced at $89 per visit, with prescriptions sent to any pharmacy, including Walmart.
- Market Reaction: Following the announcement of the partnership, Teladoc's shares rose over 7%, surpassing the 200-day moving average, indicating a positive market response to the collaboration.
- Strategic Implications: Bank of America views this partnership as a 'modest positive' for Teladoc, although it does not expect significant financial impacts in the near term; nonetheless, it enhances Teladoc's service integration within retail platforms, boosting brand visibility.
See More
Teladoc Partners with Walmart to Expand Virtual Care Services
- Collaboration Expansion: Teladoc Health announced that its virtual care services are now available through Walmart's Better Care Services platform, aiming to enhance access to healthcare, particularly for uninsured customers.
- Service Offerings: The new partnership allows Walmart customers to access various medical services, including 24/7 care, dermatology, and nutrition services, for $89 per visit, significantly improving the healthcare experience for shoppers.
- Market Strategy: Teladoc's president, Kelly Bliss, emphasized that Walmart is a primary destination for everyday needs for millions of Americans, and integrating healthcare services into the shopping experience enhances brand penetration in the market.
- Historical Collaborations: This partnership is part of Teladoc's ongoing collaboration with Walmart, following its 2025 partnership with Amazon to offer diabetes and hypertension management programs, showcasing its strategic positioning in retail and online platforms.
See More
Teladoc Health's Uncertain Future Raises Concerns
- Subpar Financial Performance: In its first quarter update, Teladoc reported a 2% year-over-year revenue decline to $613.8 million, and while the net loss per share improved from $0.53 to $0.36, the company remains unprofitable, indicating significant challenges in regaining growth momentum.
- Decline of BetterHelp Segment: Once a key growth driver, BetterHelp has seen both revenue and paying users drop by 9% year-over-year, highlighting difficulties in sustaining growth in a competitive market, which negatively impacts overall company performance.
- International Expansion Potential: Despite overall struggles, Teladoc's international revenue increased by 17% year-over-year to $122.3 million, suggesting potential for future revenue growth as the company taps into global markets.
- Uncertain Future of AI Tools: Teladoc's plans to introduce AI products to boost revenue face uncertainty regarding their effectiveness, and combined with ongoing losses and fierce competition, investors remain cautious about the company's ability to achieve profitability in the future.
See More
Teladoc Health Struggles with Financial Performance
- Declining Financial Performance: Teladoc's stock has plummeted over 90% in the past five years, with Q1 revenue dropping 2% year-over-year to $613.8 million; despite an improvement in net loss per share from $0.53 to $0.36, the company remains unprofitable, indicating ongoing financial struggles.
- BetterHelp Segment Decline: Once a key growth driver, BetterHelp has seen both revenue and paying users decline by 9% year-over-year, highlighting challenges in sustaining growth in a competitive market, which adversely affects overall performance.
- International Expansion Potential: Despite poor overall performance, Teladoc's international revenue rose 17% year-over-year to $122.3 million, indicating potential for future revenue growth as the company taps into global markets.
- Uncertain Future of AI Tools: Teladoc plans to introduce a range of AI products to boost revenue; however, given the company's history of consistent losses and intense market competition, the success of this strategy remains highly uncertain.
See More
Teladoc Stock Underperforms, Caution Advised for Investors
- Weak Revenue Growth: Teladoc's sales of $2.51 billion over the past 12 months are nearly unchanged from three years ago, indicating a lack of long-term revenue growth and suggesting lower overall business quality, which may undermine investor confidence.
- Declining User Spending: The average revenue per user (ARPU) has decreased by an average of 9% annually over the past two years, raising concerns about user engagement and signaling a potential erosion of the platform's value, which could impact future revenue growth.
- Soft Future Revenue Projections: Wall Street analysts expect Teladoc's revenue to stagnate over the next 12 months, a forecast that fails to excite the market and suggests that its newer products and services are not poised to accelerate revenue growth, potentially putting pressure on the stock price.
- Poor Market Performance: Currently trading at $6.81 per share with a forward EV/EBITDA of 5.1x, Teladoc's valuation appears fair, but the limited upside compared to potential downside risks suggests investors should consider more attractive investment opportunities.
See More
Teladoc Health Shares Rise for Seven Consecutive Days
- Stock Price Surge: Teladoc Health's shares rose over 4% on Friday, marking a seven-day winning streak, with a 22% increase since April 30, climbing from $5.95 to approximately $7.30, indicating strong market optimism about its future prospects.
- Strong Monthly Performance: Over the past month, Teladoc's stock has gained 38%, although it is up only 2.7% year-to-date, trailing the S&P 500's approximately 7% gains, reflecting a need for improvement in its relative market performance.
- Business Model Transformation: Analysts highlight that Teladoc is transitioning from a cyclical direct-to-consumer telehealth model to a higher-margin, data-driven business-to-business healthcare platform, which could enhance its long-term profitability and market valuation.
- Improved Financial Health: With improving EBITDA margins, positive free cash flow, and a stronger balance sheet, Teladoc is seen as entering a more scalable profitability phase, supporting potential future valuation re-ratings.
See More
